Total Credits: 1 including 1 AOA Category 1-A Credit(s)
This session will provide a comprehensive overview of lung cancer, covering epidemiology, risk factors, prevention, screening, diagnostic techniques, staging, prognosis, and the full spectrum of treatment options. Special emphasis will be placed on Iowa-specific data, advances in molecular profiling, and emerging diagnostic and therapeutic innovations.
Objectives:
Dr. Horning does not have any financial disclosures.
The Iowa Osteopathic Medical Association is accredited by the American Osteopathic Association to provide osteopathic continuing medical education for physicians and designates this program for a maximum of 1 AOA Category 1-A credit and will report CME and specialty credit commensurate with the extent of the physician's participation in this activity.
IOMA strives to provide continuing medical education programs to fulfill the needs of the attendees and to meet the AOA Uniform Guidelines and AOA Accreditation Requirements. Comments, questions or complaints should be put in writing and forwarded to IOMA Executive Director at ioma@ioma.org or IOMA, 1415 28th Street Suite 400, West Des Moines, IA 50266.
| Diagnosis and Treatment of Lung Cancer 2025 Slides (1.9 MB) | 65 Pages | Available after Purchase |
Dr. Neil Horning is a board-certified Pulmonary and Critical Care physician, originally from East Tennessee. He earned his medical degree from Washington University School of Medicine in St. Louis and completed his Internal Medicine residency and Pulmonary & Critical Care Medicine fellowship at Barnes–Jewish Hospital/Washington University Medical Center. Since joining MercyOne Des Moines Medical Center in 1998, Dr. Horning has played a leading role in advancing lung cancer care. In 2012, he spearheaded the development of the hospital’s Lung Cancer Screening Program, followed by the establishment of the Incidental Pulmonary Nodule Program, and the MercyOne Multidisciplinary Lung Cancer Clinic.
He currently serves as Co-Medical Director of these programs, guiding their clinical operations and ongoing growth.
